This extension followed Acadia’s Q3 2024 earnings report and reduced FY 2024 guidance, blaming slower same-store patient day growth of only 3% in October on “the recent headlines and reporting in the media.” The company also reported that it received a subpoena from the SEC. In response, the price of Acadia shares fell about 18% on October 31, 2024.

Hagens Berman urges Acadia Healthcare Company, Inc. (NASDAQ: ACHC) investors who suffered substantial losses to submit your losses now.

Expanded Class Period: Feb. 8, 2020 – Oct. 30, 2024

Lead Plaintiff Deadline: Dec. 16, 2024

Visit: www.hbsslaw.com/investor-fraud/ACHC

Contact the Firm Now: ACHC@hbsslaw.com

844-916-0895

Acadia Healthcare Company, Inc. (ACHC) Securities Class Actions:

The lawsuits claim that Acadia made false or misleading statements about its operations, including:

●      Relying on holding patients against their will, even when it wasn't medically necessary.

●      Subjecting patients at its facilities to abuse.

●      Deceiving insurance providers by billing for unnecessary patient stays.

The lawsuits follow a series of developments that have raised significant concerns about Acadia’s operations. The initial spark was a New York Times investigation published on September 1, 2024, titled "How a Leading Chain of Psychiatric Hospitals Traps Patients."

The situation escalated when, on September 27, 2024, Acadia disclosed receipt of a subpoena from the U.S. District Court for the Western District of Missouri, alongside an information request from the U.S. Attorney’s Office for the Southern District of New York. These investigations are reportedly centered on Acadia's admissions procedures, patient duration of stay, and billing practices.

Further compounding the company’s troubles, on October 18, 2024, The New York Times reported that the Department of Veterans Affairs was probing into allegations that Acadia defrauded government health insurance programs by unnecessarily prolonging patient stays.

Most recently, on October 30, 2024, Acadia announced its Q3 2024 earnings, reduced FY 2024 guidance because its same-store patient day growth slowed to just 3% in October and further said “which we believe is a result of the recent headlines and reporting in the media.” The company also reported that it received a subpoena from the SEC.

Since the reporting began on September 1, Acadia has shed approximately $3.8 billion of its market value.

Shareholder rights firm Hagens Berman is investigating the alleged claims.  “Acadia Healthcare’s alleged actions, if proven to be true, not only harm vulnerable patients but also jeopardize the interests of its investors,” said Reed Kathrein, a partner at Hagens Berman.

If you invested in Acadia Healthcare and have substantial losses, or have knowledge that may assist the firm’s investigation, submit your losses now

If you’d like more information and answers to frequently asked questions about the Acadia Healthcare case and our investigation, read more

Whistleblowers: Persons with non-public information regarding Acadia Healthcare should consider their options to help in the investigation or take advantage of the SEC Whistleblower program. Under the new program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC. For more information, call Reed Kathrein at 844-916-0895 or email ACHC@hbsslaw.com.

About Hagens Berman

Hagens Berman is a global plaintiffs’ rights complex litigation firm focusing on corporate accountability. The firm is home to a robust practice and represents investors as well as whistleblowers, workers, consumers and others in cases achieving real results for those harmed by corporate negligence and other wrongdoings. Hagens Berman’s team has secured more than $2.9 billion in this area of law. More about the firm and its successes can be found at hbsslaw.com. Follow the firm for updates and news at @ClassActionLaw.

Contact:

Reed Kathrein, 844-916-0895